partnering

News

Sanofi wagers $400m on miRecule muscular dystrophy therapy

Sanofi has added to its rare disease pipeline by licensing an antibody-RNA conjugate (ARC) for facioscapulohumeral muscular dystrophy (FSHD), a genetic muscle disorder, from US biotech miRe

News

Roche puts $70m into ArsenalBio's programmable T-cell platfo...

Roche's Genentech division has formed an R&D partnership with Arsenal Biosciences focusing on developing and refining the biotech's programmable T cell-based therapies platform.

News

Lava fires up a $700m cancer licensing deal with Seagen

While a rumoured takeover by Merck & Co has yet to materialise, Seagen is getting

News

Data-crunching specialist CytoReason signs $110m Pfizer alli...

Three years after it started working with Pfizer, artificial intelligence-powered drug discovery specialist CytoReason has converted the relationship into a lucrative, wide-ranging contract

News

Doctor in the hand shows the scanning of the lung of the person.

Bridge Bio will use Brainomix AI in lung fibrosis trial

Brainomix has reeled in another pharma partner for its artificial intelligence-powered biomarker software, used to track the performance of therapeutic interventions in clinical trials.

News

Merck makes circular RNA play with $3.5bn Orna alliance

Merck & Co has ramped up its involvement in the RNA category, partnering with US biotech Orna Therapeutics in a deal valued at up to $3.5 billion, including $150 million upfront.

Sanofi wagers $400m on miRecule muscular dystrophy therapy

Roche puts $70m into ArsenalBio's programmable T-cell platfo...

Lava fires up a $700m cancer licensing deal with Seagen

Data-crunching specialist CytoReason signs $110m Pfizer alli...

Bridge Bio will use Brainomix AI in lung fibrosis trial

Merck makes circular RNA play with $3.5bn Orna alliance

ASCO 2026: First to first line in HER-2 NSCLC, with Itziar C...

Discover a new era of healthcare panel engagement: Grounded ...

partnering

Editor's Picks